Please assess the completion status of the following clinical trial:

Trial Title: OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~1. Participants, or their legally appointed and authorized representatives, must provide written and signed informed consent form (ICF)/assent~2. Participants must be aged ≥ 12 years at the time of informed consent and, as applicable, assent~3. Participants must have a documented diagnosis of hereditary angioedema type 1 (HAE-1)/hereditary angioedema type 2 (HAE-2)~4. Participants must:~   1. Experience a minimum of 2 HAE attacks (confirmed by the Investigator) during the Screening Period~  2. Be willing to complete the participant reported outcomes (PRO) assessments throughout the study~5. Participants must have access to, and the ability to use acute medication(s) to treat angioedema attacks~Exclusion Criteria~1. Concurrent diagnosis of any other type of recurrent angioedema, including acquired, idiopathic angioedema or HAE with normal C1-INH (also known as HAE Type III)~2. Any clinically-significant abnormalities in screening laboratory values that would render a participant unsuitable for inclusion in the study~3. Treatment with another investigational drug or biological agent within 1 month or 5 half-lives, whichever is longer, of Screening~4. Participated in a prior ISIS 721744 study~5. Exposure to any of the following medications:~   1. Angiotensin-converting enzyme (ACE) inhibitors or any estrogen containing medications with systemic absorption within 4 weeks prior to Screening~  2. Chronic prophylaxis with Takhzyro, Haegarda, Cinryze and Ruconest or Orladeyo within 5 half-lives prior to Screening~  3. Oligonucleotides (including small interfering ribonucleic acid \[siRNA\]) within 4 months of Screening if single dose received, or within 12 months of Screening if multiple doses received. This exclusion does not apply to vaccines~6. Recent history (3 years) of, or current drug or alcohol abuse

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Donidalorsen: Cohort A (Type: EXPERIMENTAL): Participants will be administered donidalorsen by subcutaneous (SC) injection for up to 25 weeks.
- Donidalorsen: Cohort B (Type: EXPERIMENTAL): Participants will be administered donidalorsen by subcutaneous (SC) injection for up to 25 weeks.
- Placebo: Cohort A (Type: PLACEBO_COMPARATOR): Participants will be administered donidalorsen-matching placebo by subcutaneous (SC) injection for up to 25 weeks.
- Placebo: Cohort B (Type: PLACEBO_COMPARATOR): Participants will be administered donidalorsen-matching placebo by subcutaneous (SC) injection for up to 25 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).